Cisplatin and radiation therapy for locally advanced squamous cell carcinoma of the lung

• Published in: Cancer treatment reports Vol. 70; no. 5; p. 643
• Main Authors: Coughlin, C T, DelPrete, S A, Grace, M P, O'Donnell, J F, Quackenbush, L
• Format: Journal Article
• Language: English
• Published: United States 01.05.1986
• Subjects: Aged; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Combined Modality Therapy; Female; Humans; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Radiotherapy - adverse effects; Radiotherapy Dosage
• ISSN: 0361-5960

A pilot study was initiated to test the safety and efficacy of the simultaneous administration of high-dose cisplatin and irradiation in patients with locally advanced squamous cell carcinoma of the lung. Cisplatin was administered at 100 mg/m2 on Days 1 and 21 and was continued at 20 mg/m2 once a week to the completion of radiation therapy. Irradiation was begun on Day 22 and was administered 5 days a week for 6 weeks at a rate of 200 cGy per day to a total of 6000 cGy to the primary site, using a shrinking field technique. Of the 13 patients so treated, all but one showed objective evidence of tumor regression according to chest x-ray. Six patients are still alive from 12 to 37 months after the start of treatment, including four who are asymptomatic and without apparent tumor and two with persistent local disease. Of the seven patients who died, four had metastatic disease (including one with local recurrence as well), one (who had been resistant to therapy) had persistent local disease, and two died too early to allow comment on efficacy (although autopsy in one case showed no evidence of locoregional tumor). This program is both active and tolerable, and deserves further study.